Related Experiment Video

Updated: Nov 24, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

695

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Hematologic Malignancies

    Journal of the Advanced Practitioner in Oncology
    |December 28, 2020
    PubMed

    Insights

    Advanced practitioners review trials of new treatments for multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. The focus is on efficacy and safety in smoldering and relapsed/refractory disease states.

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Trials

    Background:

    • Multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia represent significant challenges in hematologic oncology.
    • Smoldering and relapsed/refractory disease states require continuous evaluation of novel therapeutic strategies.

    Purpose of the Study:

    • To provide an advanced practitioner perspective on current clinical trials.
    • To assess the efficacy and safety of novel agents in specific hematologic malignancies.

    Main Methods:

    • Review of ongoing and recently completed clinical trials.
    • Analysis of efficacy and safety data for novel therapeutic agents.
    • Focus on advanced practitioner insights and implications.

    Main Results:

    • Novel agents demonstrate promising efficacy in smoldering multiple myeloma.
    • Investigational therapies show potential in relapsed/refractory chronic lymphocytic leukemia.
    • Emerging treatments offer new options for acute myeloid leukemia.

    Conclusions:

    • Advanced practitioners play a crucial role in evaluating and implementing novel therapies.
    • Continued research is essential for improving outcomes in multiple myeloma, CLL, and AML.
    • Careful assessment of safety and efficacy is paramount for novel agent integration.

    More Related Videos

    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis03:40

    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

    Published on: December 8, 2023

    1.5K
    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    452

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.5K
    Bone Marrow Sampling and Transplants01:22

    Bone Marrow Sampling and Transplants

    Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
    The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
    647
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    9.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.1K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    6.2K
    Cancer Stem Cells and Tumor Maintenance02:40

    Cancer Stem Cells and Tumor Maintenance

    Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
    Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
    5.3K